673.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$676.54
Aprire:
$672.69
Volume 24 ore:
2.04M
Relative Volume:
0.73
Capitalizzazione di mercato:
$249.14B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
37.05
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
-2.34%
1M Prestazione:
+1.28%
6M Prestazione:
+44.38%
1 anno Prestazione:
+17.82%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific Inc
|
673.82 | 249.14B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
230.50 | 162.04B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
403.95 | 58.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
173.07 | 48.79B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IQV
Iqvia Holdings Inc
|
279.36 | 45.98B | 16.63B | 1.39B | 2.12B | 8.0674 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-09-03 | Iniziato | CLSA | Outperform |
| 2026-06-26 | Ripresa | Bernstein | Mkt Perform |
| 2026-06-11 | Iniziato | Piper Sandler | Neutral |
| 2026-06-03 | Downgrade | HSBC Securities | Buy → Hold |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-05-15 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
RBC Raises Price Target on Thermo Fisher Scientific to $730 From $580, Keeps Sector Perform Rating - www.marketscreener.com
Deutsche Bank Adjusts Thermo Fisher Scientific PT to $750 From $720, Maintains Buy Rating - www.marketscreener.com
Stifel Adjusts Price Target on Thermo Fisher Scientific to $775 From $650 - marketscreener.com
Barclays Adjusts Price Target on Thermo Fisher Scientific to $775 From $750 - marketscreener.com
Company News for Oct 22, 2026 - Zacks Investment Research
TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum - Yahoo Finance
Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth - BioSpectrum Asia
Thermo Fisher Scientific (TMO) Stock Faces A Q3 Earnings Disconnect - Yahoo Finance
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $701.64, Implies 2% Upside - TradingView
Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific Inc (TMO) (Q3 2026) Earnings Call Highl - GuruFocus
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Scientific Gains 4.3% on Q3 Earnings Beat - 24/7 Wall St.
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Why Is Thermo Fisher Scientific Stock Trading Higher Today?Thermo Fisher Scientific (NYSE:TMO) - Benzinga
Thermo Fisher Scientific Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Thermo Fisher reports strong 3rd-quarter results - WFMZ.com
Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings - Benzinga
Thermo Fisher Scientific Reports Third Quarter 2026 Results - BioSpace
Thermo Fisher stock gains on Q3 beat (update) (TMO:NYSE) - Seeking Alpha
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying (NYSE:TMO) - Seeking Alpha
Thermo Fisher Q3 2026 earnings show adjusted EPS up 15% to $6.68 - Quartz
Thermo Fisher Scientific Reports 9% Revenue Growth as Third-Quarter Earnings Beat Estimates - Yahoo Finance
Thermo Fisher Scientific Inc. reports results for the quarter ended September 30Earnings Summary - TradingView
Thermo Fisher Scientific Q3 2026 Earnings Call Transcript - Benzinga
Thermo Fisher Scientific Releases Q3 2026 Earnings Results - AlphaStreet
Is Thermo Fisher Scientific Inc (TMO) Overvalued After Q3 Earnin - GuruFocus
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance Singapore
Thermo Fisher Scientific Reports Third Quarter 2026 Results - Business Wire
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again - Zacks Investment Research
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings - Benzinga
Thermo Fisher Scientific Inc. stock: results due October 21 ahead of Xetra open - ad-hoc-news.de
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. expected to post earnings of $6.40 a shareEarnings Preview - TradingView
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Clinical Trial Supplies Market Forecasts Growth from $5.7 Billion (2025) to $10.7 Billion by 2033, Profiling Thermo Fisher Scientific, Catalent, Almac Group, UPS Healthcare & 6 Other Key Players - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics - Yahoo Finance
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ - The National Law Review
Thermo Fisher Scientific (TMO) Stock Gets Fair Value Bump After Q2 Driven Analyst Target Increases - Yahoo Finance
Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth - Yahoo Finance
Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery - Yahoo Finance
Academic and Government Spending Powers Thermo Fisher (TMO) - Yahoo Finance
Thermo Fisher Scientific (TMO) Q3 2026 Preview: EPS Est. $6.40, Reports October 21 - AlphaStreet
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Thermo Fisher Scientific Inc Azioni (TMO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | Officer |
Aug 31 '26 |
Proposed Sale |
614.38 |
4,133 |
2,539,233 |
0 |
| Pettiti Gianluca | President & COO |
Aug 31 '26 |
Sale |
614.38 |
4,133 |
2,539,233 |
23,216 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Sale |
627.05 |
275 |
172,439 |
123,925 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Option Exercise |
309.63 |
275 |
85,148 |
124,200 |
| CASPER MARC N | Officer |
Aug 24 '26 |
Proposed Sale |
627.05 |
275 |
172,438 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 21 '26 |
Sale |
626.92 |
10,000 |
6,269,153 |
123,925 |
| CASPER MARC N | Officer |
Aug 21 '26 |
Proposed Sale |
626.91 |
10,000 |
6,269,123 |
0 |
| CASPER MARC N | Officer |
Aug 20 '26 |
Proposed Sale |
629.27 |
10,000 |
6,292,653 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):